| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| October 27th, 2004 | 26 | Yes |
Popular Name: CELECOXIB CELECOXIB
Find On: PubMed — Wikipedia — Google
CAS Numbers: 169590-42-5 , 169590-42-5; 184007-95-2; 194044-54-7 , 184007-95-2 , 194044-54-7 , [169590-42-5]
169590-42-5; C07589; Celecoxib
169590-42-5; Celebrex (TN); Celecoxib (JAN/USAN/INN); D00567
169590-42-5; CPD000550473; Celecoxib; SAM002589995
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-pyrazol-1-yl]benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
Benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-
benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
Celebrex; Celecoxib; Celocoxib
CPD000550473; Celecoxib; SAM002589995
METHYLPHENYLTRIFLUOROMETHYLPYRAZOLYLBENZENESULFONAMID
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 3.61 | 5.33 | -11.94 | 2 | 5 | 0 | 78 | 381.379 | 4 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| ALOGPS_SOLUBILITY | 5.03e-03 g/l | DrugBank-approved |
| purity | 9.500000000000000e+001 | Enamine Building Blocks Enamine Building Blocks |
| Purity | 98% | Matrix Scientific |
| biological_use | Also used in the treatment of familial adenomatous polyposis | IBScreen Bioactives |
| Indications | analgesic, NSAID | KeyOrganics Bioactives |
| Therapy | antiarthritic, cyclooxygenase2 inhibitor | SMDC Iconix |
| Target | COX | Selleck Chemicals |
| mechanism | Cyclooxygenase-2 (COX-2) inhibitor | IBScreen Bioactives |
| Patent Database Links | EP1064948; EP1064964; EP1088550; EP1167355; EP1405646; EP1471054; EP1498140; EP1518555; EP1525883; EP1528058; EP1537858; EP1538164; EP1547650; EP1593386; EP1602334; EP1611877; EP1627639; EP1629835; EP1637137; EP1640003; EP1661560; EP1698330; EP1712220; EP | ChEBI |
| biological_use | Inhibits colon carcinogenesis in animal models | IBScreen Bioactives |
| Warnings | IRRITANT | Matrix Scientific |
| PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : LightBiologicals; NCC_SUPPLIER_STRUCTURE_ID : C-3950; NCC_SUPPLIER_SAMPLE_COMMENTS : YELLOW CRISTALLINE POWDER | NIH Clinical Collection via PubChem |
| biological_use | Non-steroidal antiinflammatory drug | IBScreen Bioactives IBScreen Bioactives |
| Reactome Database Links | REACT_150255 | ChEBI |
| PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: LightBiologicals; SUPPLIER_STRUCTURE_ID: C-3950; SUPPLIER_COMMENTS: YELLOW CRISTALLINE POWDER | NIH Clinical Collection via PubChem |
| UniProt Database Links | STK11_MOUSE | ChEBI |
| biological_use | Used in the treatment of rheumatoid arthritis and osteoarthritis | IBScreen Bioactives |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| CAH-1-A | Carbonic Anhydrase (cluster #1 Of 2), Archaea | Archaea | 140 | 0.37 | Binding ≤ 10μM |
| CYNT-1-B | Carbonic Anhydrase (cluster #1 Of 3), Bacterial | Bacteria | 713 | 0.33 | Binding ≤ 10μM |
| B5SU02-2-E | Alpha Carbonic Anhydrase (cluster #2 Of 6), Eukaryotic | Eukaryotes | 34 | 0.40 | Binding ≤ 10μM |
| C0IX24-1-E | Carbonic Anhydrase (cluster #1 Of 5), Eukaryotic | Eukaryotes | 690 | 0.33 | Binding ≤ 10μM |
| CAH12-1-E | Carbonic Anhydrase XII (cluster #1 Of 9), Eukaryotic | Eukaryotes | 18 | 0.42 | Binding ≤ 10μM |
| CAH13-1-E | Carbonic Anhydrase XIII (cluster #1 Of 7), Eukaryotic | Eukaryotes | 98 | 0.38 | Binding ≤ 10μM |
| CAH14-1-E | Carbonic Anhydrase XIV (cluster #1 Of 8), Eukaryotic | Eukaryotes | 689 | 0.33 | Binding ≤ 10μM |
| CAH15-2-E | Carbonic Anhydrase 15 (cluster #2 Of 6), Eukaryotic | Eukaryotes | 45 | 0.40 | Binding ≤ 10μM |
| CAH2-1-E | Carbonic Anhydrase II (cluster #1 Of 15), Eukaryotic | Eukaryotes | 21 | 0.41 | Binding ≤ 10μM |
| CAH4-1-E | Carbonic Anhydrase IV (cluster #1 Of 16), Eukaryotic | Eukaryotes | 290 | 0.35 | Binding ≤ 10μM |
| CAH5A-1-E | Carbonic Anhydrase VA (cluster #1 Of 10), Eukaryotic | Eukaryotes | 794 | 0.33 | Binding ≤ 10μM |
| CAH5B-1-E | Carbonic Anhydrase VB (cluster #1 Of 9), Eukaryotic | Eukaryotes | 93 | 0.38 | Binding ≤ 10μM |
| CAH6-2-E | Carbonic Anhydrase VI (cluster #2 Of 8), Eukaryotic | Eukaryotes | 94 | 0.38 | Binding ≤ 10μM |
| CAH7-1-E | Carbonic Anhydrase VII (cluster #1 Of 8), Eukaryotic | Eukaryotes | 2170 | 0.30 | Binding ≤ 10μM |
| CAH9-1-E | Carbonic Anhydrase IX (cluster #1 Of 11), Eukaryotic | Eukaryotes | 16 | 0.42 | Binding ≤ 10μM |
| COX2-1-E | Cytochrome C Oxidase Subunit 2 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 60 | 0.39 | Binding ≤ 10μM |
| MK14-1-E | MAP Kinase P38 Alpha (cluster #1 Of 3), Eukaryotic | Eukaryotes | 810 | 0.33 | Binding ≤ 10μM |
| PGH1-1-E | Cyclooxygenase-1 (cluster #1 Of 6), Eukaryotic | Eukaryotes | 9730 | 0.27 | Binding ≤ 10μM |
| PGH2-4-E | Cyclooxygenase-2 (cluster #4 Of 8), Eukaryotic | Eukaryotes | 9 | 0.43 | Binding ≤ 10μM |
| Q8HZR1-1-E | Cyclooxygenase-1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 5570 | 0.28 | Binding ≤ 10μM |
| Q8SPQ9-2-E | Cyclooxygenase-2 (cluster #2 Of 2), Eukaryotic | Eukaryotes | 900 | 0.33 | Binding ≤ 10μM |
| CAH2-1-E | Carbonic Anhydrase II (cluster #1 Of 2), Eukaryotic | Eukaryotes | 21 | 0.41 | Functional ≤ 10μM |
| CAH4-1-E | Carbonic Anhydrase IV (cluster #1 Of 2), Eukaryotic | Eukaryotes | 290 | 0.35 | Functional ≤ 10μM |
| PGH1-1-E | Cyclooxygenase-1 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 2000 | 0.31 | Functional ≤ 10μM |
| PGH2-1-E | Cyclooxygenase-2 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 3600 | 0.29 | Functional ≤ 10μM |
| CP2C9-1-E | Cytochrome P450 2C9 (cluster #1 Of 3), Eukaryotic | Eukaryotes | 10000 | 0.27 | ADME/T ≤ 10μM |
| CAN-1-F | Carbonic Anhydrase (cluster #1 Of 3), Fungal | Fungi | 108 | 0.38 | Binding ≤ 10μM |
| Q5AJ71-1-F | Carbonic Anhydrase (cluster #1 Of 4), Fungal | Fungi | 21 | 0.41 | Binding ≤ 10μM |
| Z100741-1-O | MC9 (Mast Cells) (cluster #1 Of 2), Other | Other | 400 | 0.34 | Functional ≤ 10μM |
| Z50587-1-O | Homo Sapiens (cluster #1 Of 9), Other | Other | 6670 | 0.28 | Functional ≤ 10μM |
| Z80548-1-O | THP-1 (Acute Monocytic Leukemia Cells) (cluster #1 Of 5), Other | Other | 5000 | 0.29 | Functional ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| B5SU02_9CNID | B5SU02 | Alpha Carbonic Anhydrase, 9cnid | 34.2 | 0.40 | Binding ≤ 1μM |
| CAN_YEAST | P53615 | Carbonic Anhydrase, Yeast | 108 | 0.38 | Binding ≤ 1μM |
| CAH_METTE | P40881 | Carbonic Anhydrase, Mette | 140 | 0.37 | Binding ≤ 1μM |
| CYNT_MYCTU | O53573 | Carbonic Anhydrase, Myctu | 713 | 0.33 | Binding ≤ 1μM |
| C0IX24_9CNID | C0IX24 | Carbonic Anhydrase, 9cnid | 690 | 0.33 | Binding ≤ 1μM |
| Q5AJ71_CANAL | Q5AJ71 | Carbonic Anhydrase, Canal | 21 | 0.41 | Binding ≤ 1μM |
| CAH15_MOUSE | Q99N23 | Carbonic Anhydrase 15, Mouse | 45 | 0.40 | Binding ≤ 1μM |
| CAH2_HUMAN | P00918 | Carbonic Anhydrase II, Human | 21 | 0.41 | Binding ≤ 1μM |
| CAH4_BOVIN | Q95323 | Carbonic Anhydrase IV, Bovin | 290 | 0.35 | Binding ≤ 1μM |
| CAH4_HUMAN | P22748 | Carbonic Anhydrase IV, Human | 880 | 0.33 | Binding ≤ 1μM |
| CAH9_HUMAN | Q16790 | Carbonic Anhydrase IX, Human | 16 | 0.42 | Binding ≤ 1μM |
| CAH5A_HUMAN | P35218 | Carbonic Anhydrase VA, Human | 794 | 0.33 | Binding ≤ 1μM |
| CAH5B_HUMAN | Q9Y2D0 | Carbonic Anhydrase VB, Human | 93 | 0.38 | Binding ≤ 1μM |
| CAH6_HUMAN | P23280 | Carbonic Anhydrase VI, Human | 94 | 0.38 | Binding ≤ 1μM |
| CAH12_HUMAN | O43570 | Carbonic Anhydrase XII, Human | 18 | 0.42 | Binding ≤ 1μM |
| CAH13_HUMAN | Q8N1Q1 | Carbonic Anhydrase XIII, Human | 98 | 0.38 | Binding ≤ 1μM |
| CAH14_HUMAN | Q9ULX7 | Carbonic Anhydrase XIV, Human | 689 | 0.33 | Binding ≤ 1μM |
| PGH1_SHEEP | P05979 | Cyclooxygenase-1, Sheep | 210 | 0.36 | Binding ≤ 1μM |
| PGH1_HUMAN | P23219 | Cyclooxygenase-1, Human | 3.54 | 0.46 | Binding ≤ 1μM |
| PGH1_MOUSE | P22437 | Cyclooxygenase-1, Mouse | 0.7 | 0.49 | Binding ≤ 1μM |
| PGH2_MOUSE | Q05769 | Cyclooxygenase-2, Mouse | 0.51 | 0.50 | Binding ≤ 1μM |
| PGH2_SHEEP | P79208 | Cyclooxygenase-2, Sheep | 100 | 0.38 | Binding ≤ 1μM |
| PGH2_BOVIN | O62698 | Cyclooxygenase-2, Bovin | 57 | 0.39 | Binding ≤ 1μM |
| PGH2_HUMAN | P35354 | Cyclooxygenase-2, Human | 0.519995997 | 0.50 | Binding ≤ 1μM |
| Q8SPQ9_CANFA | Q8SPQ9 | Cyclooxygenase-2, Canine | 900 | 0.33 | Binding ≤ 1μM |
| COX2_SHEEP | O78750 | Cytochrome C Oxidase Subunit 2, Sheep | 60 | 0.39 | Binding ≤ 1μM |
| MK14_HUMAN | Q16539 | MAP Kinase P38 Alpha, Human | 810 | 0.33 | Binding ≤ 1μM |
| B5SU02_9CNID | B5SU02 | Alpha Carbonic Anhydrase, 9cnid | 34.2 | 0.40 | Binding ≤ 10μM |
| CAH_METTE | P40881 | Carbonic Anhydrase, Mette | 1010 | 0.32 | Binding ≤ 10μM |
| CYNT_MYCTU | O53573 | Carbonic Anhydrase, Myctu | 713 | 0.33 | Binding ≤ 10μM |
| Q5AJ71_CANAL | Q5AJ71 | Carbonic Anhydrase, Canal | 1017 | 0.32 | Binding ≤ 10μM |
| C0IX24_9CNID | C0IX24 | Carbonic Anhydrase, 9cnid | 690 | 0.33 | Binding ≤ 10μM |
| CAN_YEAST | P53615 | Carbonic Anhydrase, Yeast | 108 | 0.38 | Binding ≤ 10μM |
| CAH15_MOUSE | Q99N23 | Carbonic Anhydrase 15, Mouse | 45 | 0.40 | Binding ≤ 10μM |
| CAH2_HUMAN | P00918 | Carbonic Anhydrase II, Human | 21 | 0.41 | Binding ≤ 10μM |
| CAH4_BOVIN | Q95323 | Carbonic Anhydrase IV, Bovin | 290 | 0.35 | Binding ≤ 10μM |
| CAH4_HUMAN | P22748 | Carbonic Anhydrase IV, Human | 880 | 0.33 | Binding ≤ 10μM |
| CAH9_HUMAN | Q16790 | Carbonic Anhydrase IX, Human | 16 | 0.42 | Binding ≤ 10μM |
| CAH5A_HUMAN | P35218 | Carbonic Anhydrase VA, Human | 794 | 0.33 | Binding ≤ 10μM |
| CAH5B_HUMAN | Q9Y2D0 | Carbonic Anhydrase VB, Human | 93 | 0.38 | Binding ≤ 10μM |
| CAH6_HUMAN | P23280 | Carbonic Anhydrase VI, Human | 94 | 0.38 | Binding ≤ 10μM |
| CAH7_HUMAN | P43166 | Carbonic Anhydrase VII, Human | 2170 | 0.30 | Binding ≤ 10μM |
| CAH12_HUMAN | O43570 | Carbonic Anhydrase XII, Human | 18 | 0.42 | Binding ≤ 10μM |
| CAH13_HUMAN | Q8N1Q1 | Carbonic Anhydrase XIII, Human | 98 | 0.38 | Binding ≤ 10μM |
| CAH14_HUMAN | Q9ULX7 | Carbonic Anhydrase XIV, Human | 689 | 0.33 | Binding ≤ 10μM |
| PGH1_BOVIN | O62664 | Cyclooxygenase-1, Bovin | 7700 | 0.28 | Binding ≤ 10μM |
| Q8HZR1_CANFA | Q8HZR1 | Cyclooxygenase-1, Canine | 5570 | 0.28 | Binding ≤ 10μM |
| PGH1_HUMAN | P23219 | Cyclooxygenase-1, Human | 1689 | 0.31 | Binding ≤ 10μM |
| PGH1_MOUSE | P22437 | Cyclooxygenase-1, Mouse | 0.7 | 0.49 | Binding ≤ 10μM |
| PGH1_SHEEP | P05979 | Cyclooxygenase-1, Sheep | 210 | 0.36 | Binding ≤ 10μM |
| PGH2_BOVIN | O62698 | Cyclooxygenase-2, Bovin | 57 | 0.39 | Binding ≤ 10μM |
| Q8SPQ9_CANFA | Q8SPQ9 | Cyclooxygenase-2, Canine | 900 | 0.33 | Binding ≤ 10μM |
| PGH2_RAT | P35355 | Cyclooxygenase-2, Rat | 1100 | 0.32 | Binding ≤ 10μM |
| PGH2_HUMAN | P35354 | Cyclooxygenase-2, Human | 0.519995997 | 0.50 | Binding ≤ 10μM |
| PGH2_MOUSE | Q05769 | Cyclooxygenase-2, Mouse | 0.51 | 0.50 | Binding ≤ 10μM |
| PGH2_SHEEP | P79208 | Cyclooxygenase-2, Sheep | 100 | 0.38 | Binding ≤ 10μM |
| COX2_SHEEP | O78750 | Cytochrome C Oxidase Subunit 2, Sheep | 60 | 0.39 | Binding ≤ 10μM |
| MK14_HUMAN | Q16539 | MAP Kinase P38 Alpha, Human | 810 | 0.33 | Binding ≤ 10μM |
| CAH2_HUMAN | P00918 | Carbonic Anhydrase II, Human | 21 | 0.41 | Functional ≤ 10μM |
| CAH4_BOVIN | Q95323 | Carbonic Anhydrase IV, Bovin | 290 | 0.35 | Functional ≤ 10μM |
| PGH1_HUMAN | P23219 | Cyclooxygenase-1, Human | 1880 | 0.31 | Functional ≤ 10μM |
| PGH2_HUMAN | P35354 | Cyclooxygenase-2, Human | 110 | 0.37 | Functional ≤ 10μM |
| Z50587 | Z50587 | Homo Sapiens | 164 | 0.37 | Functional ≤ 10μM |
| Z100741 | Z100741 | MC9 (Mast Cells) | 300 | 0.35 | Functional ≤ 10μM |
| Z80548 | Z80548 | THP-1 (Acute Monocytic Leukemia Cells) | 5000 | 0.29 | Functional ≤ 10μM |
| CP2C9_HUMAN | P11712 | Cytochrome P450 2C9, Human | 10000 | 0.27 | ADME/T ≤ 10μM |
| Description | Species |
|---|---|
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) |
| Description | Species |
|---|---|
| activated TAK1 mediates p38 MAPK activation | |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | |
| Activation of the AP-1 family of transcription factors | |
| ADP signalling through P2Y purinoceptor 1 | |
| CDO in myogenesis | |
| COX reactions | |
| CYP2E1 reactions | |
| DSCAM interactions | |
| ERK/MAPK targets | |
| Erythrocytes take up carbon dioxide and release oxygen | |
| Erythrocytes take up oxygen and release carbon dioxide | |
| KSRP destabilizes mRNA | |
| Nicotinamide salvaging | |
| NOD1/2 Signaling Pathway | |
| Oxidative Stress Induced Senescence | |
| p38MAPK events | |
| Platelet sensitization by LDL | |
| Regulation of gene expression by Hypoxia-inducible Factor | |
| Reversible hydration of carbon dioxide | |
| Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE) | |
| Synthesis of 15-eicosatetraenoic acid derivatives | |
| Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) | |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | |
| VEGFA-VEGFR2 Pathway | |
| Xenobiotics |